CRISM Therapeutics raises £2.5M ($3.4M) in share placing

What's the deal? Crism TherapeuticsDealroom has a profile for this one. Try Dealroom → Corporation has raised £2.5M ($3.4M) through a share placing, the cancer treatment-focused company announced on Tuesday. It plans to use the funds to advance its projects.

The signal: Crism Therapeutics' implantable biodegradable drug delivery approach — designed for sustained, local chemotherapy release in solid tumours — sits at the intersection of oncology and medtech, a niche that has drawn growing interest from investors seeking differentiated cancer treatment platforms. The £2.5M raise, while modest, gives the early-growth-stage AIM-listed company runway to advance a technology that could sidestep some of the systemic side-effect challenges facing conventional chemotherapy.

Read more: law360.com